Journal of Adolescent Health
Volume 21, Issue 3 , Pages 143-146 , September 1997

Counseling sexually active teenagers treated with potential human teratogens

    MD
  • Kathleen Shilalukey

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Miriam Kaufman

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Susan Bradley

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • William H. Francombe

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Koffi Amankwah

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Eudice Goldberg

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Neil Shear

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Nancy F. Olivieri

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
  • , MD
  • Gideon Koren

      Affiliations

    • Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hematology, Adolescent Medicine, the Hospital for Sick Children, Canada
    • Toronto Hospital, Toronto, Canada
    • University of Toronto, Toronto, Canada
    • Corresponding Author InformationAddress reprint requests to: Gideon Koren, M.D., Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada.

,Accepted 13 December 1996.

References 

  1. Newman CGH. Teratogen update: Clinical aspects of thalidomide embryopathy—a continuing preoccupation. Teratology. 1985;32:133–144
  2. Koren G, Nulman I. Teratogenic drugs and chemicals in humans. In: Koren G editors. Maternal-Fetal Toxicology. 2nd ed.. New York: Marcel Dekker; 1994;p. 33–48
  3. Pastuszak A, Koren G. The retinoids of pregnancy prevention program. In: Koren G editors. Retinoids in Clinical Practice. The Risk-Benefit Ratio. New York: Marcel Dekker; 1993;p. 147–175
  4. Koren G. Retinoic acid embryopathy. N Engl J Med. 1986;315:262
  5. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med. 1990;323:713–719
  6. Ciba Pharmaceutical Company . Official literature on new drugs deferoxamine mesylate: A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1967;10:595–596
  7. Ciba-Geigy Report on Desferal to the FDA. 1966;
  8. Thomas RM, Skalioka AE. Successful pregnancy in transfusion dependent thalassemia. Arch Dis Child. 1980;55:572–574
  9. Martin K. Successful pregnancy in β-thalassemia major. Aust Ped J. 1983;19:182–183
  10. Dolfin G, Lumare A, Tinetti E, et al. Problemi ostetrici ed etamologici in una gestante affetta da beta-thalassemia intemedia. Min Gin. 1983;35:227–230
  11. Abstract Kyriakou D, Papanicolaou C, Gyparaki M, et al. Absence of desferrioxamine teratogenicity in a thalassemic patient. In: Second International Conference on Thalassemia and the Haemoglobinopathies. Herakleion (Crete) Greece. Oct. 21–24, 1987;p. 109
  12. McElhatton PR, Roberts JC, Sullivan FM. The consequences of iron overdose and its treatment with desferrioxamine in pregnancy. Hum Exp Toxicol. 1991;10:251–259
  13. Turk J, Arks S, Hryhorczuk DO. Successful therapy of iron intoxication in pregnancy with intravenous deferoxamine and whole bowel irrigation. Vet Hum Toxicol. 1993;35:441–444
  14. In: Schnebli HP editors. Ciba-Geigy final report: Preclinical evaluation of CG P 37 391 (L1). Biology Report ERS 62/93. 1993;p. 19
  15. Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Ped Hem Oncol. 1992;14:48–56
  16. Planeczky M, Slap G, Forke C, et al. The use of levonorgestrel implant (Norplant) for contraception in adolescent mothers. N Engl J Med. 1994;331:1201–1206
  17. Schlossberger N. Validity of self-report of pubertal maturation in early adolescents. J Adolesc Health. 1992;13:109–113
  18. Kaufman M. Easy for You to Say. Key-Porter Books. 1995;

PII: S1054-139X(97)00041-4

doi: 10.1016/S1054-139X(97)00041-4

Journal of Adolescent Health
Volume 21, Issue 3 , Pages 143-146 , September 1997